1. Catalog
  2. Nodes
  3. a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one")

a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one")

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one
Namespace
mesh
Namespace Version
20181007
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns

Appears in Networks 2

Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer's disease and schizophrenia. v1.0.0

This file encodes the article Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia by Choi et al, 2014

M1 muscarinic acetylcholine receptor in Alzheimer’s disease v1.0.0

This file encodes the article M1 muscarinic acetylcholine receptor in Alzheimer’s disease by Jiang et al, 2014

In-Edges 1

a(MESH:"Antipsychotic Agents") association a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one") View Subject | View Object

The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122]. PubMed:24590577

Appears in Networks:

Out-Edges 3

a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one") increases act(p(HGNC:CHRM1)) View Subject | View Object

Subsequent optimization produced two analogs of AC-42 (AC-260584 and 77-LH-28-1), which maintained M1 selectivity and possessed properties suitable for use in animal models. Both AC-260584 and 77-LH-28-1 displayed antipsychotic and cognition-enhancing efficacy in pre-clinical models PubMed:24511233

Appears in Networks:

a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one") increases bp(GO:cognition) View Subject | View Object

The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122]. PubMed:24590577

Appears in Networks:

a(MESH:"4-(3-(4-butylpiperidin-1-yl)propyl)-7-fluoro-4H-benzo(1,4)oxazin-3-one") association a(MESH:"Antipsychotic Agents") View Subject | View Object

The M1 mAChR agonist AC-260584 was recently reported to be orally bioavailable with favorable antipsychotic and cognition-enhancing effects[118, 122]. PubMed:24590577

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.